New antibody COM701 aims to keep ovarian cancer at bay

NCT ID NCT06888921

Recruiting now Disease control Sponsor: Compugen Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This clinical trial tests whether the experimental antibody COM701 can delay the return of ovarian cancer in people whose cancer has come back but still responds to platinum chemotherapy. About 60 participants will receive COM701 or a placebo every three weeks as maintenance therapy. The study will measure how long the cancer stays under control and monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: COM701 (an experimental antibody)
What this could lead to: If it works, this could provide a new maintenance option to delay ovarian cancer recurrence after chemotherapy.
What could go wrong: This is an early Phase 1/2 trial with only 60 participants, so results may not apply broadly. Side effects are still being studied, and the drug may not slow cancer progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER OVARIAN CANCER RECURRENT

Contacts and locations

Locations

Assuta Medical Center
RECRUITING

Ashdod, 7747629, Israel
Avera Cancer Institute
RECRUITING

Sioux Falls, South Dakota, 57105, United States
Centre Eugene Marquis
RECRUITING

Rennes, 35042, France
Centre Hospitalier Regional et Universitaire de Besancon - Hopital Jean-Minjoz
RECRUITING

Besançon, France, 25000, France
Centre Oscar Lambret
RECRUITING

Lille, 59000, France
Corewell Health
RECRUITING

Grand Rapids, Michigan, 49503, United States
Georgia Cancer Center at Augusta University
RECRUITING

Augusta, Georgia, 30912, United States
Gustave Roussy
RECRUITING

Villejuif, 94800, France
Hadassah, University Hospital Ein Kerem
RECRUITING

Jerusalem, 9112001, Israel
Hospices Civils de Lyon- Centre Hospitalier Lyon Sud
RECRUITING

Pierre-Bénite, 69310, France
Institut Paoli-Calmettes
RECRUITING

Marseille, 13009, France
Institut de Cancerologie de l'Ouest- Site Rene Gauducheau
RECRUITING

Saint-Herblain, 44805, France
Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center- Main Campus
RECRUITING

New York, New York, 10065, United States
Northwestern Memorial Hospital
RECRUITING

Warrenville, Illinois, 60555, United States
OU Health Stephenson Cancer Center
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run
RECRUITING

Hilliard, Ohio, 43026, United States
Oncopole Claudius Regaud
RECRUITING

Toulouse, France, 31059, France
Rambam Health Care Campus
RECRUITING

Haifa, 3109601, Israel
Shaare Zedek Medical Center
RECRUITING

Jerusalem, 9103102, Israel
The Chaim Sheba Medical Center
RECRUITING

Ramat Gan, 5265601, Israel
The Edith Wolfson Medical Center
RECRUITING

Holon, 5822012, Israel
The University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
UPMC Magee- Womens Hospital
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
UVA Comprehensive Cancer Center
RECRUITING

Charlottesville, Virginia, 22903, United States
University of Rochester Medical Center
RECRUITING

Rochester, New York, 14642, United States
West Cancer Center
WITHDRAWN

Germantown, Tennessee, 38138, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.